title: Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis.
abstract: BCR/ABL fluorescent in situ hybridization study of chronic myeloid leukemia (CML) and Philadelphia(+) (Ph(+)) acute lymphoid leukemia (ALL) indicated that approximately 9% of patients exhibited an atypical hybridization pattern consistent with a submicroscopic deletion of the 5' region of ABL and the 3' region of the BCR genes on the 9q(+) chromosome. The CML patients with deletions had a shorter survival time and a high relapse rate following bone marrow transplant. Since deletions are associated with both Ph(+) CML and ALL, it seemed probable that other leukemia-associated genomic rearrangements may also have submicroscopic deletions. This hypothesis was confirmed by the detection of deletions of the 3' regions of the CBFB and the MLL genes in AML M4 patients with inv(16) and in patients with ALL and AML associated with MLL gene translocations, respectively. In contrast, analysis of the AML M3 group of patients and AML M2 showed that similar large deletions were not frequently associated with the t(15;17) or t(8;21) translocations. Analysis of sequence data from each of the breakpoint regions suggested that large submicroscopic deletions occur in regions with a high overall density of Alu sequence repeats. These findings are the first to show that the process of deletion formation is not disease specific in leukemia and also implicate that the presence of repetitive DNA in the vicinity of breakpoint regions may facilitate the generation of submicroscopic deletions. Such deletions could lead to the loss of one or more genes, and the associated haploinsufficiency may result in the observed differences in clinical behavior. (Blood. 2001;97:3581-3588)
authors.affiliation: Ontario Cancer Institute, Princess Margaret Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5G 2M9 Canada.
authors.forename: E
authors.initials: E
authors.lastname: Kolomietz
authors.forename: J
authors.initials: J
authors.lastname: Al-Maghrabi
authors.forename: S
authors.initials: S
authors.lastname: Brennan
authors.forename: J
authors.initials: J
authors.lastname: Karaskova
authors.forename: S
authors.initials: S
authors.lastname: Minkin
authors.forename: J
authors.initials: J
authors.lastname: Lipton
authors.forename: J A
authors.initials: JA
authors.lastname: Squire
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002869:Chromosome Aberrations; D002885:Chromosomes, Human, Pair 16; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D050658:Core Binding Factor beta Subunit; D020732:Cytogenetic Analysis; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D017353:Gene Deletion; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007938:Leukemia / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics; D008297:Male; D008875:Middle Aged; D018995:Myosin Heavy Chains / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics; D011379:Prognosis; D012008:Recurrence; D017422:Sequence Analysis, DNA; D015996:Survival Rate; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000235:genetics; D014178:Translocation, Genetic
chemical_list: C493692:CBFB protein, human; D050658:Core Binding Factor beta Subunit; D004268:DNA-Binding Proteins; D050656:Transcription Factor AP-2; D014157:Transcription Factors; D016044:Fusion Proteins, bcr-abl; D018995:Myosin Heavy Chains